Dec. 9, 2020 – A chemically tweaked version of the psychedelic drug ibogaine appears to relieve depression and addiction symptoms without producing hallucinations or other dangerous side effects.
The results of a study in rodents suggest it may be possible to make psychedelic drugs safe enough to become mainstream treatments for psychiatric disorders, the authors report Wednesday in the journal Nature.
“What we need is a medicine that is so safe that you can take it home and put it in your medicine cabinet just like you would aspirin,” says David Olson, the paper’s senior author and an assistant professor at the University of California, Davis. “And that’s really what we were trying to achieve.”
The success with ibogaine is “a promising first step,” says Gabriela Manzano, a postdoctoral fellow at Weill Cornell Medicine in New York and a co-author of a commentary on the study. “This provides a road map on how we could start tweaking these chemical compounds to make them very useful in the clinic,” she says. “Keep the good parts, get rid of the bad parts.”
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…